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Abstract
Background: Sunitinib is a multi-targeted tyrosine kinase inhibitor that is approved for treatment of renal cell
carcinoma as an oral anticancer drug. Therapeutic drug monitoring of total sunitinib (sunitinib and N-desethyl
sunitinib) is used in our hospital to improve therapeutic efficacy, while preventing adverse effects. Here, we report
the first case of a patient with metastatic renal cell carcinoma undergoing hemodialysis and presenting severe
adverse events induced by the accumulation of N-desethyl sunitinib.
Case presentation: A 60-year-old Japanese man was diagnosed with metastatic renal cell carcinoma requiring
hemodialysis. On day 26 of the first cycle of sunitinib therapy, our patient presented grade 3 thrombocytopenia
and leukopenia, which required interruption of therapy although the plasma levels of total sunitinib in the patient
were less than the effective concentration of 50 ng/mL. The elimination half-life of sunitinib was normal at 50.8
hours, but that of N-desethyl sunitinib was an extended 211.4 hours. Moreover, the N-desethyl sunitinib/sunitinib
trough level ratio was higher than 1.0. We attribute our patient’s severe adverse events to the excessive
accumulation of N-desethyl sunitinib owing to its delayed excretion. Although the reason for the delayed excretion
of N-desethyl sunitinib in this patient was unknown, it may have been caused by genetic polymorphisms related to
the pharmacokinetics of sunitinib rather than the hemodialysis. In this case, the patient was homozygous for the
ABCG2 421C allele, but was capable of potentially harboring polymorphisms in other genes, such as ABCB1, an efflux
pump of sunitinib. In addition, even though there is no clear evidence, urinary excretion of the metabolic products
of N-desethyl sunitinib could be inhibited by the interaction of transporters such as the organic ion transporter.
Conclusions: The monitoring of not only total sunitinib concentration but also N-desethyl sunitinib concentration
and their elimination half-lives during sunitinib therapy is recommended to avoid critical adverse events.
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Background
Renal cell carcinoma (RCC) is the most common type of
kidney cancer. RCC represents approximately 90% of all
renal tumors, and 85% of these RCC consist of clear cell
tumors. Recently, many tyrosine kinase inhibitors have
been approved for treatment of RCC [1]. Sunitinib, an
oral anticancer drug, is a tyrosine kinase inhibitor with
multiple targets, including: vascular endothelial growth
factor receptors (VEGFRs-1, -2, and -3), platelet-derived
growth factor receptors (PDGFRs-α and -β), and the
FMS-like tyrosine kinase 3 receptor [2]. Although suniti-
nib shows a high objective response rate and signifi-
cantly prolongs the median progression-free survival in
the first-line treatment of RCC, sunitinib use has been
associated with various adverse events, such as diarrhea,
fatigue, vomiting, leukopenia, neutropenia, and
thrombocytopenia [3].
Recently, therapeutic drug monitoring (TDM) of anti-
cancer drugs has been reported to improve therapeutic
efficacy while preventing the presentation of adverse ef-
fects [4]. Sunitinib is metabolized primarily by cyto-
chrome P450 (CYP) 3A4 to N-desethyl sunitinib, which
shows an activity similar to that of sunitinib [5, 6].
Therefore, TDM of sunitinib is commonly evaluated as
total sunitinib (sunitinib and N-desethyl sunitinib) in
plasma [5]. The effective blood trough concentration of
total sunitinib has been reported in the range of 50–100
ng/mL. For sunitinib to inhibit phosphorylation of
VEGFR and PDGFR and thus present antitumor activity,
a concentration of more than 50 ng/mL total sunitinib is
required [2]. In contrast, patients with plasma levels
equal to or exceeding 100 ng/mL total sunitinib have
frequently developed grade 3 or higher toxicities, such
as asthenia and anorexia [7, 8]. The difference between
toxicities induced by sunitinib and N-desethyl sunitinib
is unknown, although sunitinib has been reported to be
more dermatotoxic than N-desethyl sunitinib is in some
patients [9]. Since patients with renal function impair-
ment are usually excluded from clinical trials, pharmaco-
kinetic and pharmacodynamic analyses of sunitinib in
such patients are limited. However, a few studies have
reported that the pharmacokinetics of sunitinib in
patients with severe renal impairment is similar to that
of patients with normal renal function [10]. In addition,
a case report indicated that the pharmacokinetics of
sunitinib and N-desethyl sunitinib were not affected
by hemodialysis, and sunitinib therapy continued
safely [11, 12].
Herein, we report the case of a patient with metastatic
RCC undergoing hemodialysis who presented severe
adverse events while in treatment with sunitinib. TDM
suggests that these events were the result of accumula-
tion of an active sunitinib metabolite even though his
total sunitinib levels were below 50 ng/mL.
Case presentation
A 60-year-old Japanese man was diagnosed with RCC 11
years ago. Initial treatment consisted of a partial left
nephrectomy for clear cell carcinoma (pT2 pV0 pM0).
Eight years later, our patient presented a cystic kidney
and was referred to hemodialysis. Subsequently, our
patient presented RCC with bone and brain metastasis
and initiated sunitinib therapy. Our patient was
prescribed 25 mg sunitinib once daily for 4 weeks of a 6-
week cycle. His Eastern Cooperative Oncology Group
(ECOG) score was 1. Our patient reported suffering in-
somnia and bone pain caused by bone metastasis.
One week after starting sunitinib therapy, our
patient experienced hand-foot syndrome and grade 1
hypertension as per the Common Terminology
Criteria for Adverse Events (version 4.0). On day 26
of first cycle, sunitinib administration was interrupted
because our patient presented adverse events of grade
3 thrombocytopenia (platelet count, 49,000/μL) and
leukopenia (white blood cell count, 1600/μL) (Fig. 1b
and c). On day 21, the concentrations of sunitinib, N-
desethyl sunitinib and trough level ratio (N-desethyl
sunitinib/sunitinib) at steady state were 21.1 ng/mL,
21.4 ng/mL, and 1.0, respectively, and 7.9 ng/mL,
16.9 ng/mL, and 2.1, respectively, 4 days after suniti-
nib withdrawal, as shown in Fig. 1a. Moreover, the
elimination half-lives of sunitinib and N-desethyl
sunitinib were 50.8 hours and 211.4 hours, respect-
ively. After recovering from the hematotoxic events
described above, our patient was prescribed axitinib, a
second-line drug for metastatic RCC.
With the patient’s written informed consent, blood
samples were collected immediately before administra-
tion of sunitinib. Plasma levels of sunitinib and N-
desethyl sunitinib were measured using liquid
chromatography-tandem mass spectrometry (LC-MS/
MS). The LC-MS/MS assay was carried out using a
liquid chromatography system consisting of a Nexera
chromatograph (Shimadzu, Kyoto, Japan) coupled to an
API 5000 triple-quadrupole tandem mass spectrometer
(AB Sciex, Framingham, MA, USA). Our patient was
administered benzodiazepines for insomnia, and acet-
aminophen and tramadol for bone pain. Lansoprazole
was started at the same time as the sunitinib treatment,
but he continued taking it even after discontinuation of
sunitinib. His body weight and body mass index at the
start of treatment were 64.3 kg and 23.3 kg/m2, respect-
ively. The laboratory analyses while he was undergoing
sunitinib therapy yielded the following results: aspartate
aminotransferase, 18.7 ± 2.2 U/L; alanine aminotransfer-
ase, 14.7 ± 2.0 U/L. Our patient received hemodialysis
treatment for 4 hours, three times a week, through a
polysulfone dialyzer (VPS-15HA); the blood flow rate
was constant at 200 mL/min and the dialysis flow rate
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was 550 mL/min. In addition, his serum creatinine was
7.7 mg/dL before sunitinib treatment started, 7.0 mg/dL
immediately before interruption and 8.8 mg/dL after 1
week of discontinuation.
Genomic deoxyribonucleic acid (DNA) was extracted
from the blood and genotyped using direct sequencing
of the ATP-binding cassette subfamily G member 2
(ABCG2). His genotype was wild type for the ABCG2
421C > A polymorphism.
Discussion
This is the first case in which the accumulation of N-
desethyl sunitinib was reported to cause serious adverse
events, even when the total sunitinib concentration was
under the reported trough value of 50 ng/mL. Our data
suggest that in this patient, N-desethyl sunitinib accu-
mulated because of delayed excretion, resulting in the
described adverse effects. The patient’s N-desethyl suni-
tinib plasma levels (21.4 ng/mL) while taking 25 mg su-
nitinib were higher than the steady-state levels (18.8 ng/
mL) of patients administered 50 mg sunitinib daily [7].
The elimination half-lives of sunitinib and N-desethyl
sunitinib have been reported as 70 hours and 111 hours,
respectively, in patients with end-stage renal disease re-
quiring hemodialysis [10]; the corresponding half-lives of
this patient were 51 hours and 211 hours. Moreover, the
reported trough level ratio (N-desethyl sunitinib/suniti-
nib) is 0.43 [7], but was above 1.0 in this patient. In
addition, it has been reported that thrombocytopenia is
more frequently associated with N-desethyl sunitinib ra-
ther than sunitinib [13]. On the basis of these data, we
conclude that the cause of the grade 3 hematologic tox-
icities was the accumulation of N-desethyl sunitinib.
Despite the fact that the use of concomitant medica-
tions, health supplements, and grapefruit have been
found to affect the main metabolic enzyme of sunitinib,
CYP 3A4, our patient did not consume them; therefore,
it was considered unlikely that the accumulation of N-
desethyl sunitinib was the result of any of these factors.
Although the reason for the delayed excretion of N-
desethyl sunitinib in this patient was unknown, we sug-
gest it was caused by genetic polymorphisms affecting
the pharmacokinetics of sunitinib rather than by the
hemodialysis. It has been reported that the gene poly-
morphism in ABCG2 421C > A can induce severe
toxicity by delaying the excretion of sunitinib [14], but
Fig. 1 Change in (a) plasma concentration of total (sunitinib + N-desethyl sunitinib), sunitinib and N-desethyl sunitinib, (b) platelet count, and (c)
white blood cell count in the patient after starting sunitinib therapy
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the patient in this case had a wild-type ABCG2. How-
ever, there may be other gene polymorphisms, such as
those described for ATP-binding cassette subfamily B
member 1, which function as an efflux pump of suniti-
nib and can thus affect the clinical outcome [15].
Furthermore, N-desethyl sunitinib is further metabolized
and excreted in the urine [16, 17]. This excretion process
can be inhibited by the interaction with transporters
such as the organic ion transporter. In addition, previous
research has shown that the incidence of severe
hematological toxicities is demonstrably higher in
Japanese patients than in other populations, but that the
pharmacokinetic data from Japanese patients is similar
to that of Caucasians [18]. Thus, ethnic differences in
sunitinib-induced hematologic toxicities could be attrib-
uted to factors other than the pharmacokinetic genetic
background.
Although the evidence for use of TDM of sunitinib in
a clinical setting is limited, this case report demonstrates
that TDM can be useful for predicting and avoiding se-
vere adverse events. Further studies would be needed to
select patients suitable for TDM with gene polymor-
phisms, severe adverse events, and no antitumor effects.
Conclusions
The monitoring of not only total sunitinib concentration
but also N-desethyl sunitinib concentration, as well as
their elimination half-lives during sunitinib therapy is
recommended to avoid critical adverse events.
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